



Q3 2024

Business Update and Financial Results

13 November 2024

EURONEXT : IPH.PA NASDAQ : IPHA

Disclaimer on Forward-Looking Information and Risk Factors

This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF website (www.amf-france.org) or on the Company’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company’s potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

Q3 2024 Business Update and Financial Results Conference call agenda

Strategic Overview and Outlook

Jonathan Dickinson

Chief Executive Officer, Chairman of the Executive Board

Clinical Pipeline Progress

Sonia Quaratino

Chief Medical Officer

ANKET®, ADC & monalizumab

Yannis Morel

Chief Operating Officer

Upcoming Catalysts &
Closing Remarks

Arvind Sood


President of US Operations

Q&A

All speakers

Frederic Lombard

Chief Financial Officer




Jonathan Dickinson appointed CEO of Innate Pharma

- Experienced pharmaceutical and biotech executive
- Extensive experience gained working for Incyte Biosciences, ARIAD Pharmaceuticals, Bristol-Myers Squibb, Roche, Novartis, and Sandoz,

“My purpose is rooted in transforming innovation into tangible improvements for patients with serious diseases, while fostering a culture of trust, empowerment and excellence within my teams.”





Strategic Overview and Outlook

Jonathan Dickinson

Chief Executive Officer

Chairman of the Executive Board



Scientific innovation drives our strategy

Leveraging our expertise in **innate immunity and antibody engineering** to develop novel, first-in-class therapies for cancer, advancing a diverse pipeline of proprietary and partnered assets with major biopharma companies



Lacutamab

*Phase 2 at ASCO & ASH
Registrational plans underway*


ANKET® & ADC

*IPH6501 at ASCO
IPH4502 Phase 1 preparation
SAR'579 progress to Phase 2 & 1L
combo*

Monalizumab

*Phase 3 trial underway,
further Phase 2 data at
ASCO & WCLC*

Our robust pipeline of proprietary & partnered assets




Data across innovative oncology pipeline presented at SITC and ASH 2024



- **Harnessing NK Cells in Cancer** Therapies, Eric Vivier, CSO (Oral)
- Preclinical data supporting the evaluation of **IPH6501** in relapsed or refractory B-NHL subtypes and post-CAR-T therapy (Poster)
- Preclinical data supporting **IPH4502**, a novel and differentiated exatecan-Based ADC in Nectin-4 expressing tumors (Poster)



- Health-related quality of life in patients with R/R CTCL treated by **lacutamab** in the TELLOMAK Phase 2 trial (Oral)
- Translational analysis from the TELLOMAK Phase 2 trial with **lacutamab** (Poster)



Pipeline Progress

Sonia Quaratino

Chief Medical Officer



Proprietary key clinical pipeline progress

Key clinical pipeline

Lacutamab



Phase 2

IPH6501 (CD20-IL2v)




Phase 1

IPH4502 (Nectin-4)



IND cleared

Research



Lacutamab | Clinical Trials

A potential new standard of care in the T-cell lymphomas expressing KIR3DL2

Cutaneous T cell lymphoma

Sézary syndrome

~90% KIR3DL2
expression $\geq 1\%$

Mycosis fungoides

TELLOMAK Phase 2 Trial

Sézary syndrome N=56

Minimum of 2 prior therapies, including mogamulizumab



Mycosis fungoides N=107

At least 2 prior systemic therapies



Sézary syndrome
Phase 2

LTFU 2025



Mycosis fungoides
Phase 2

LTFU 2025

Peripheral T cell lymphoma

~18,000 patients
~50% KIR3DL2
expression $\geq 1\%$


KILT Phase 2 Trial

Combination with GEMOX chemotherapy (gemcitabine in combination with oxaliplatin)
versus GEMOX alone




Data 2025

TELLOMAK data support lacutamab as a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy



IPH6501, a novel CD20-targeting tetraspecific natural killer cell engager issued from ANKET[®] platform, has started clinical study in B-cell malignancies



Phase 1/2 first-in-human, multicenter,
in Patients With Relapsed and/or
Refractory Non-Hodgkin Lymphoma
NCT06088654

First patient dosed in March 2024

IPH6501

IL2v-armed
Tetra-specific
ANKET[®]
targeting CD20

- ❖ **Innovative MOA** → Triggers NK cells for self-expansion (IL2v) and cancer elimination
- ❖ **Differentiate vs allogeneic NK cells** → Drive proliferation of own patient NK cells (no lymphodepletion required)
- ❖ **Overcome resistance (CD16 loss)** → Ensure constant activation of intra-tumoral NK cells through NKp46
- ❖ **Bystander tumor cell killing** → Stimulate NK cell functions and eliminate CD20-negative tumor cells

IPH6501 potential path forward

2025

Generate safety data and preliminary signals of activity in CD20+ B-NHL

2026

Confirm activity signal with dose optimized in CD20+ B-NHL & select B-NHL subtypes for expansion cohorts

2027 &
beyond

Expansion study in selected B-NHL subtypes & explore combination in earlier lines and other CD20+ B-NHL

Data will inform next steps

IPH4502 potential path forward

2024
2025

IND cleared and generate preliminary Phase 1 safety data


2026

Establish preliminary activity signal in nectin-4 expressing tumor types with low and high expression levels

Beyond

Dose optimization and exploration of combination in expansion cohorts

Data will inform next steps



ANKET[®], ADC, monalizumab

Yannis Morel

Chief Operating Officer



Multiple ANKET[®] programs targeting hematological malignancies and solid tumors

Growing clinical pipeline



SAR'579 / IPH6101 (CD123)

sanofi

Phase 1 / 2

SAR'514 / IPH6401 (BCMA)

sanofi

Phase 1 / 2

IPH6501 (CD20-IL2v)

 innate

Phase 1 / 2

IPH67 (Undisclosed, solid tumor)

 innate

Research

IPH81 (Undisclosed)

 innate

Research

IPH62 (B7-H3)

sanofi


Research

Option

sanofi

Research

Multiple Targets

 innate


Research

SAR443579 progress to Ph2 in R/R AML

New Phase 1/2 in 1L AML in combination with azacytidin + venetoclax

Supporting preclinical data at 


Data across innovative oncology pipeline presented at SITC 2024 Annual Meeting



- **Harnessing NK Cells in Cancer** Therapies
Eric Vivier, CSO (Oral)
- Preclinical data supporting the evaluation of **IPH6501** in relapsed or refractory B-NHL subtypes and post-CAR-T therapy (Poster)
- Preclinical data supporting **IPH4502**, a novel and differentiated exatecan-Based ADC in Nectin-4 expressing tumors (Poster)


Preclinical data support evaluation of IPH6501 in relapsed or refractory B-NHL subtypes and post-CAR-T therapy

NKp46 provides a **key advantage** for **IPH6501** over CD20-targeting Abs




IPH6501 has potential **across subtypes** of B-NHL, including in **post CAR-T** setting

**Killing by NK cells
from R/R B-NHL patients**



NKp46 expression



IPH4502, a novel and differentiated exatecan-based ADC in Nectin-4 expressing tumors

In vivo bystander killing





**Address heterogeneous
Nectin-4 expression**

Efficacy in model of EV
acquired resistance



Address post-EV patients



Monalizumab development in lung cancer

Clinical studies
in
NSCLC

Phase 2 NeoCOAST

Stg I-III NSCLC

monalizumab + durvalumab

In progress

Phase 2 NeoCOAST-2

Stg II-III NSCLC

Arm 2: monalizumab + durvalumab +/- CTx

In progress

Phase 2 COAST

Unresect. Stg III NSCLC

monalizumab + durvalumab



999 pts

Phase 3 PACIFIC-9

Unresect. Stg III NSCLC

3 arms including Arm B: monalizumab + durvalumab

STAGE I

STAGE II

STAGE III

STAGE IV

NSCLC Resectable


NSCLC Unresectable

Metastatic

Phase 2
clinical
data

NeoCOAST-2 preliminary analysis


2024 World Conference
on Lung Cancer




Arm 2: Neoadjuvant durvalumab + monalizumab + CTx and
Adjuvant durvalumab + monalizumab

COAST updated results

2024 ASCO[®]
ANNUAL MEETING



durvalumab ± oleclumab or monalizumab



Upcoming Catalysts and Closing Remarks

Arvind Sood

President of US Operations



Newsflow and upcoming catalysts

Delivering across our strategic objectives

Proprietary

- **Lacutamab TELLOMAK | Phase 2 FDA interaction completed**
- IPH5301 (CD73) | Phase 1 data at ESMO 2024

- **Lacutamab TELLOMAK | Next steps**
- Lacutamab PTCL | Phase 2 Data

- IPH6501 ANKET® (CD20 IL2v) | Phase 1 progress

- **IPH6501 ANKET® (CD20 IL2v) | Phase 1 data**

- **IPH45 ADC (Nectin-4) | Phase 1 start**

- **IPH45 ADC (Nectin-4) | Phase 1 data**

2024

>2025

Partnered

- SAR'579 / IPH6101 ANKET® (CD123) | Phase 2 progress (Sanofi)
- SAR'514 / IPH6401 ANKET® (BCMA) | Phase 1 progress (Sanofi)

- Monalizumab PACIFIC-9 | Phase 3 readout (AZ)
- IPH5201 (CD39) MATISSE | Phase 2 readout (AZ)
- 3 ANKET® licensed | Next steps (Sanofi)
- 1 ANKET® option | (Sanofi)

Key Takeaways


Create value for patients and shareholders

Clinical stage company with growing differentiated first-in-class pipeline


- **LACUTAMAB**
 - Encouraging FDA feedback on regulatory pathway
- **EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS**
 - Phase 1/2 clinical trial underway with IPH6501, a proprietary 2nd generation ANKET® in B-cell NHL
 - SAR'579 progressed to Phase 2 by Sanofi, Front line combination with venetoclax study initiated
- **PURSUING DIFFERENTIATED ADCS**
 - IPH4502, anti nectin-4 Antibody Drug Conjugate progressing towards Phase 1 in Q1 2025

Cash position of €96.4m* as of September 30, 2024 with anticipated runway to end 2025

*Including short term investments (€14.0m) and non-current financial instruments (€10.3m)



Q&A





Thank you

www.innate-pharma.com
investors@innate-pharma.fr

EURONEXT : IPH.PA NASDAQ : IPHA